Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

DT-216

Other · developed by Design Therapeutics

Phase 1 Most advanced trial (none active)

DSGN Developer

1 Registered trials

What is DT-216?

DT-216 is an agent given by intravenous injection. It is studied in Friedreich Ataxia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: Design Therapeutics, Inc. (DSGN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05573698	Phase 1	Friedreich Ataxia	Completed	DSGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Friedreich Ataxia

More from Design Therapeutics

DT-168 Phase 2 DT-216P2 Phase 1/2

Sources

ClinicalTrials.gov NCT05573698

Updated Oct 11, 2026. Something wrong or missing? Report it on the DSGN page.

Follow DSGN, the company behind DT-216

See DSGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DSGN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z